Avidity biosciences reports first quarter 2021 financial results and recent highlights

La jolla, calif., may 12, 2021 /prnewswire/ -- avidity biosciences, inc. (nasdaq: rna), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called antibody oligonucleotide conjugates (aocs™), today reported financial results for the first quarter ended march 31, 2021 and highlighted recent corporate progress.
RNA Ratings Summary
RNA Quant Ranking